Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial
Article 2017 en
Authors
VE
Vidal Essebag
RP
Riccardo Proietti
DB
David H. Birnie
Abstract
1 min read
In patients treated with dabigatran undergoing CIED surgery, interruption of dabigatran is associated with similar or lower incidence of pocket hematoma, when compared with warfarin interruption without or with heparin bridging, respectively. Whether uninterrupted dabigatran can reduce pocket hematoma or ischemic stroke remains to be evaluated.
Annapoorna Kini, George Dangas, Usman Baber, Yuliya Vengrenyuk, David E. Kandzari, Martin B. Leon, Marie‐Claude Morice, Patrick W. Serruys, A. Pieter Kappetein, Joseph F. Sabik, Ovidiu Dressler, Roxana Mehran, Samin K. Sharma, Gregg W. Stone
Laura Mauri, P S Steg, Deepak L. Bhatt, Stefan H. Hohnloser, Matias Nordaby, Corinna Miede, Takeshi Kimura, Professor Gregory Lip, Jonas Oldgren, Jurriën M. ten Berg, Christopher P. Cannon
Serge Doucet, E. Marc Jolicœur, Patrick W. Serruys, Michael Ragosta, Irving L. Kron, Werner Scholtz, Jochen Börgermann, Yiran Zhang, Thomas McAndrew, Joseph F. Sabik, A. Pieter Kappetein, Gregg W. Stone
Ioanna Kosmidou, Björn Redfors, Shmuel Chen, Aaron Crowley, Nicholas Lembo, Dimitri Karmpaliotis, W. Morris Brown, Eric Maupas, Nicolas Dürrleman, Alpesh Shah, Michael J. Reardon, Ovidiu Dressler, Ori Ben‐Yehuda, A. Pieter Kappetein, Joseph F. Sabik, Patrick W. Serruys, Gregg W. Stone
Discussion(0)
No comments yet. Be the first to comment.